<DOC>
	<DOCNO>NCT01725386</DOCNO>
	<brief_summary>This observational study evaluate routine clinical use safety efficacy capecitabine ( XelodaÂ® ) participants metastatic advance breast cancer . Eligible participant follow 24 month .</brief_summary>
	<brief_title>An Observational Study Xeloda ( Capecitabine ) Participants With Metastatic Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult female participant , &gt; /= 18 year age Cytologic/histopathologic confirm diagnosis metastatic breast cancer Prescribed capecitabine routine clinical practice Informed consent sign Participation clinical trial History severe unexpected reaction fluoropyrimidine therapy Hypersensitivity capecitabine excipients fluorouracil Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Pregnant lactate woman Severe leucopenia , neutropenia , thrombocytopenia Severe hepatic impairment Severe renal impairment ( creatinine clearance 30 ml/min ) Treatment sorivudine chemically related analogue , brivudine Refusal give consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>